Cargando…

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

BACKGROUND: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve treatment efficacy. Here, we explored the effect of androgen receptor blocka...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lückerath, Katharina, Wei, Liu, Fendler, Wolfgang P., Evans-Axelsson, Susan, Stuparu, Andreea D., Slavik, Roger, Mona, Christine E., Calais, Jeremie, Rettig, Matthew, Reiter, Robert E., Herrmann, Ken, Radu, Caius G., Czernin, Johannes, Eiber, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206308/ https://www.ncbi.nlm.nih.gov/pubmed/30374743 http://dx.doi.org/10.1186/s13550-018-0451-z

Ejemplares similares

Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer
por: Meyer, Catherine, et al.
Publicado: (2023)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
por: Fendler, Wolfgang P., et al.
Publicado: (2020)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
por: Calais, Jeremie, et al.
Publicado: (2021)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study
por: Stuparu, Andreea D., et al.
Publicado: (2020)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
por: Gafita, Andrei, et al.
Publicado: (2022)

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study
por: Sonni, Ida, et al.
Publicado: (2023)

Evaluation of SUV normalized by lean body mass (SUL) in (68)Ga-PSMA11 PET/CT: a bi-centric analysis
por: Gafita, Andrei, et al.
Publicado: (2019)

PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
por: Ferdinandus, Justin, et al.
Publicado: (2022)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study
por: Murthy, Vishnu, et al.
Publicado: (2023)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

Positron Emission Tomography Reporter Genes and Reporter Probes: Gene and Cell Therapy Applications
por: Yaghoubi, Shahriar S., et al.
Publicado: (2012)

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
por: Lütje, Susanne, et al.
Publicado: (2019)

A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
por: Kuo, Phillip H., et al.
Publicado: (2023)

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
por: Schottelius, Margret, et al.
Publicado: (2015)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fn9t44rch3pa1ljbkuldboscn4